Vedanta Biosciences confirmed a significant reduction in headcount as it reallocates remaining resources to advance VE303, its lead live bacterial consortium for prevention of recurrent Clostridioides difficile infection, toward a planned Phase 3 completion. The company cited strong Phase 2 data as the rationale for concentrating efforts and paused or wound down other programs. The move follows prior restructuring and underscores funding pressure for microbiome therapeutics despite the commercial success of competitors such as Seres’ Vowst. VE303 is a defined consortium of commensal strains intended to restore colonization resistance against pathogenic C. difficile; Vedanta said the refocus preserves runway for the pivotal trial.